Diuretic Use in Hemodialysis Patients With Residual Renal Function (DIURESED)
End Stage Renal Disease on Dialysis
About this trial
This is an interventional treatment trial for End Stage Renal Disease on Dialysis
Eligibility Criteria
Inclusion Criteria: Adult patients (age 18 years or older), who are within their first 12 months of chronic (expected to need dialysis for at least 6 months), in-centre hemodialysis therapy, and Residual renal function defined as 24-hour urine volume >200cc, and Life expectancy of at least 6 months, and Participants must be able to understand the consent process and be able to sign a consent form or have a substitute decision maker who is able to understand and sign consent on their behalf. In the case of non-English speaking participants, a translator service will be used to provide study information and obtain consent. Exclusion Criteria: Unable to complete baseline urine collection Documented allergy or adverse reaction to furosemide or chlorthalidone. Unable to take oral medications Patients expecting to change modality (peritoneal dialysis, home dialysis) or to receive a renal transplant in the next 6 weeks History of hypokalemia (<3.0 mmol/L), hypomagnesemia (<0.6mmol/L), or hypocalcaemia (<1.9mmol/L) in preceding 2 weeks. Already participating in another study and one of the studies could interfere with the other study Use of loop, or thiazide diuretic medications in the last week (if a patient is on chronic diuretics, they would need to be discontinued for 1 week before starting the trial)
Sites / Locations
- University of AlbertaRecruiting
Arms of the Study
Arm 1
Experimental
Diuretic Therapy